Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Primary CNS non-Hodgkin lymphoma (PCNSL) has been shown to be increasing in incidence. This appears to be a consequence of the increasing population of those older than 65 years of age in whom PCNSL occurs most often. PCNSL often has a favorable response to treatment and aggressive management may result in extended survival and, in a proportion of patients less than 65 years of age, cure. The majority of neuro-oncologist's advocate utilizing high-dose methotrexate (HD-MTX) as a platform for the chemotherapy treatment of these neoplasms. In this review, the literature regarding HDHMTX as a treatment for PCNSL is summarized as are the pharmacological principles of HD-MTX.
Green
Myke R
MR
University of South Florida, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, Florida 33611, USA. greenmr@moffitt.usf.edu
Chowdhary
Sajeel
S
Lombardi
Kristina M
KM
Chalmers
Lisa M
LM
Chamberlain
Marc
M
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate